Plasma phosphorylated tau 217, the blood marker this paper has previously reported as an Alzheimer's test, has now been examined inside Parkinson's disease, and in two separate cohorts it behaved as a marker of Alzheimer's copathology rather than of Lewy pathology. In an observational study published in Annals of Neurology on 18 March 2026, Thomas Tropea and colleagues at the University of Pennsylvania measured P-tau217 in stored samples from participants followed between 2007 and 2024: 46 people with pathologically confirmed Parkinson's disease and 10 with dementia with Lewy bodies, plus a clinical series of 173 people with Parkinson's disease and 64 controls. Among the autopsy-confirmed cases, median P-tau217 was 0.274 U/mL in those with intermediate or high Alzheimer's neuropathological change and 0.110 U/mL in those without, and the marker separated the two groups with an area under the curve of 0.84. In the clinical series, 154 participants had repeat Mattis Dementia Rating Scale testing for up to 16 years (mean 5.3 years), and a higher baseline P-tau217 was associated with a greater risk of cognitive progression (hazard ratio 1.597, p = 0.003). This is an observational association, not evidence that the tau measured in blood causes the decline.
The second study, published in npj Parkinson's Disease on 10 April 2026 by Amanda Smith, Sara Lorkiewicz, Burak Arslan and colleagues, asked a narrower question in a group defined by biology rather than by clinical diagnosis. It was cross-sectional and included 253 participants, 180 in a Stanford University discovery cohort and 73 in clinical validation cohorts drawn from Stanford and the Sant Pau Initiative on Neurodegeneration. Neuronal synuclein disease status was set by a cerebrospinal fluid alpha-synuclein seed amplification assay and amyloid status by cerebrospinal fluid Abeta42/40. Of the five plasma markers tested, pTau217 performed best at detecting amyloid-beta, with an area under the curve of 0.92 (95 percent confidence interval 0.81 to 0.98), and the authors report that applying their cut points as a pre-screen in the clinically diagnosed Lewy body cohorts would have avoided confirmatory amyloid PET or spinal fluid testing in 41 to 56 percent of participants.
What neither paper claims is that the test reads Lewy pathology. In the Stanford discovery cohort, plasma pTau217, pTau181, Abeta42/40 and GFAP differed according to amyloid status regardless of whether synuclein seeding was present, which is the point: the marker follows the Alzheimer's process that often travels alongside Parkinson's, not the alpha-synuclein process that defines it. Between a quarter and a half of Lewy body cases carry enough amyloid and tau at death for a secondary Alzheimer's diagnosis, and that copathology has been linked in earlier work to worse cognition and shorter survival, which is why both groups frame the marker as a way of finding those people.
Both studies are observational, single or two centre, and small in the places that matter most: 56 autopsy-confirmed cases in the Pennsylvania series, and a cross-sectional design in the synuclein disease study that cannot speak to change over time. Cut points are assay specific and are not interchangeable between laboratories or platforms. The Pennsylvania work was supported by the National Institutes of Health and by Eli Lilly, which funded the P-tau217 measurements, and several coauthors, including Mark Mintun, are Lilly employees. The Pennsylvania authors state that future work will look at imaging and clinical outcomes with a view to trials of amyloid-targeting therapies in Lewy body disorders; no such trial has yet reported that treating amyloid changes the course of Parkinson's disease.